1/15
01:03 pm
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at BTIG Research.
1/14
08:42 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/14
08:42 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/13
08:42 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
1/13
01:16 am
bcax
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial [Yahoo! Finance]
Medium
Report
Bicara Therapeutics Touts Breakthrough Ficerafusp Data, Picks 1,500 mg Dose for FORTIFY-HNS Trial [Yahoo! Finance]
1/12
08:27 am
bcax
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook [Yahoo! Finance]
Medium
Report
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook [Yahoo! Finance]
1/12
08:00 am
bcax
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
Medium
Report
Bicara Therapeutics Announces Phase 3 Optimal Dose and Provides 2026 Corporate Outlook
1/9
06:10 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
1/8
08:02 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
12/24
07:01 pm
bcax
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions [Yahoo! Finance]
Low
Report
Bicara Therapeutics (BCAX) Valuation After Dual Biotechnology Index Additions [Yahoo! Finance]
12/22
06:30 pm
bcax
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices [Yahoo! Finance]
Medium
Report
The Bull Case For Bicara Therapeutics (BCAX) Could Change Following Dual Inclusion In Major Biotech Indices [Yahoo! Finance]
12/19
05:57 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) was upgraded by analysts at Mizuho to a "hold" rating.
12/17
07:01 pm
bcax
Bicara Therapeutics (NASDAQ:BCAX) was given a new $18.00 price target on by analysts at Mizuho.
Low
Report
Bicara Therapeutics (NASDAQ:BCAX) was given a new $18.00 price target on by analysts at Mizuho.
12/15
08:00 am
bcax
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
Low
Report
Bicara Therapeutics to Present at the J.P. Morgan 2026 Annual Healthcare Conference on Monday, January 12
12/6
08:00 am
bcax
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
Medium
Report
Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026
12/1
07:00 am
bcax
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
Medium
Report
Bicara Therapeutics Announces Publication of an Abstract with Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab in 1L HPV-negative R/M HNSCC at ESMO Asia 2025
11/11
09:44 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its price target raised by analysts at Wells Fargo & Company from $8.00 to $11.00. They now have an "equal weight" rating on the stock.
11/10
09:04 am
bcax
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
Medium
Report
Bicara Therapeutics (NASDAQ:BCAX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $30.00 price target on the stock.
11/10
09:03 am
bcax
Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]
Medium
Report
Bicara Therapeutics GAAP EPS of -$0.67 [Seeking Alpha]
11/10
07:41 am
bcax
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update [Yahoo! Finance]
11/10
07:30 am
bcax
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
10/27
08:30 am
bcax
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Low
Report
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
10/27
08:30 am
bcax
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology
Low
Report
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology